U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963398) titled 'A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors' on April 29.
Brief Summary: HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: HS-10529
Participants in all subjucts will receive HS-10529
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....